CL2022000990A1 - Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1 - Google Patents

Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1

Info

Publication number
CL2022000990A1
CL2022000990A1 CL2022000990A CL2022000990A CL2022000990A1 CL 2022000990 A1 CL2022000990 A1 CL 2022000990A1 CL 2022000990 A CL2022000990 A CL 2022000990A CL 2022000990 A CL2022000990 A CL 2022000990A CL 2022000990 A1 CL2022000990 A1 CL 2022000990A1
Authority
CL
Chile
Prior art keywords
combination
cxcr7
receptor modulator
cxcr7 antagonist
antagonist
Prior art date
Application number
CL2022000990A
Other languages
English (en)
Inventor
Laetitia Pouzol
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2022000990A1 publication Critical patent/CL2022000990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)

Abstract

Compuesto (1-pirimidin-2-il-ciclopropil)-amida del ácido (3S,4S)-1-ciclopropilmetil-4-{[5-(2,4-difluoro-fenil)-isoxazol-3-carbonil]-amino}-piperidin-3-carboxílico y su uso como modulador del receptor de CXCL11/CXCL12, CXCR7, en combinación con otros ingredientes o agentes, en la prevención o tratamiento de enfermedades y trastornos donde tanto la expresión de CXCR7 o sus ligandos y S1P desempeñan una función. Composiciones farmacéuticas que comprenden el compuesto.
CL2022000990A 2019-10-31 2022-04-20 Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1 CL2022000990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2019079932 2019-10-31

Publications (1)

Publication Number Publication Date
CL2022000990A1 true CL2022000990A1 (es) 2023-01-27

Family

ID=75715765

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000990A CL2022000990A1 (es) 2019-10-31 2022-04-20 Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1

Country Status (11)

Country Link
EP (1) EP4051250A1 (es)
JP (1) JP2023501217A (es)
KR (1) KR20220093330A (es)
CN (1) CN114599363A (es)
AU (1) AU2020372647A1 (es)
CA (1) CA3156298A1 (es)
CL (1) CL2022000990A1 (es)
IL (1) IL292529A (es)
MX (1) MX2022005014A (es)
TW (1) TW202131921A (es)
WO (1) WO2021084068A1 (es)

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960692B2 (en) 2001-09-27 2005-11-01 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN100567275C (zh) 2003-11-21 2009-12-09 埃科特莱茵药品有限公司 作为免疫抑制剂的5-(苯基-(z)-亚基)-噻唑烷-4-酮衍生物
BRPI0507944A (pt) 2004-02-24 2007-07-24 Sankyo Co composição farmacêutica
KR20070085465A (ko) 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
EP2371811B1 (en) 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
ATE524432T1 (de) 2005-12-15 2011-09-15 Mitsubishi Tanabe Pharma Corp Aminverbindung und deren verwendung für medizinische zwecke
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
CN103087004A (zh) 2006-11-23 2013-05-08 埃科特莱茵药品有限公司 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
ES2617628T5 (es) 2008-03-17 2020-06-01 Actelion Pharmaceuticals Ltd Régimen de dosificación para un agonista selectivo del receptor de S1P1
EP3059226A1 (en) 2008-03-24 2016-08-24 Kyorin Pharmaceutical Co., Ltd. 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride crystal
KR20180023049A (ko) 2008-07-23 2018-03-06 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
GB0819182D0 (en) 2008-10-20 2008-11-26 Actelion Pharmaceuticals Ltd Crystalline forms
AU2009315735B2 (en) 2008-11-11 2013-01-10 Novartis Ag Salts of fingolimod
CN107233336A (zh) 2008-11-11 2017-10-10 诺华股份有限公司 芬戈莫德的结晶形式
RU2011129229A (ru) 2008-12-18 2013-01-27 Новартис Аг Новые соли
IL294514A (en) 2008-12-18 2022-09-01 Novartis Ag 1-[4-[1[(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid mipomarate salt
CA2746764A1 (en) 2008-12-18 2010-06-24 Novartis Ag New polymorphic form of 1- (4- { l- [ (e) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
DK2379067T3 (en) 2008-12-22 2015-12-07 Novartis Ag Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
CA3105857C (en) 2008-12-22 2023-08-01 Novartis Ag Dosage regimen of an s1p receptor agonist
CN102471328B (zh) 2009-07-16 2015-04-01 埃科特莱茵药品有限公司 吡啶-4-基衍生物
MX2012003752A (es) 2009-09-29 2012-06-01 Novartis Ag Metodo y sistema para accesar datos de pacientes.
ES2858337T3 (es) 2009-11-13 2021-09-30 Receptos Llc Moduladores selectivos del receptor de fosfato de esfingosina 1 y métodos de síntesis quiral
WO2011094008A1 (en) 2010-01-27 2011-08-04 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
AU2012324867B2 (en) 2011-10-21 2015-09-10 Novartis Ag Dosage regimen for an S1P receptor modulator or agonist
JP5753333B1 (ja) 2012-05-22 2015-07-22 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ２−シクロペンチル−６−メトキシ−イソニコチン酸の新規な製造方法
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
EP3062792A1 (en) 2013-11-01 2016-09-07 Celgene International II Sarl Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN106456552A (zh) 2014-04-10 2017-02-22 诺华股份有限公司 S1p调节剂的立即释放剂量方案
MY188764A (en) 2014-12-11 2021-12-30 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
EP4445956A2 (en) 2015-01-06 2024-10-16 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
EP3298008B1 (en) 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
WO2016209809A1 (en) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
MA45782B1 (fr) 2016-07-28 2021-12-31 Idorsia Pharmaceuticals Ltd Modulateurs du récepteur de cxcr7 pipéridine
JP6961595B2 (ja) 2016-07-29 2021-11-05 田辺三菱製薬株式会社 ４−アルコキシ−３−トリフルオロメチルベンジルアルコールの製造方法
CN110612292A (zh) 2017-04-07 2019-12-24 杭州领业医药科技有限公司 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
EP3621610A1 (en) 2017-05-08 2020-03-18 Celgene International II Sàrl Sphingosine 1 phosphate receptor agonists for neuroprotection
PT3630738T (pt) 2017-05-22 2023-10-24 Egyt Gyogyszervegyeszeti Gyar Processo para a produção de ozanimod
WO2019058290A1 (en) 2017-09-20 2019-03-28 Suven Life Sciences Limited IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND
US11390583B2 (en) 2017-09-27 2022-07-19 Dr. Reddy's Laboratories Limited Process for preparation of Siponimod, its salts and solid state forms thereof
WO2019094409A1 (en) 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Salts and solid state forms of ozanimod
EP3743422B1 (en) 2018-01-26 2024-03-13 Idorsia Pharmaceuticals Ltd Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Also Published As

Publication number Publication date
TW202131921A (zh) 2021-09-01
KR20220093330A (ko) 2022-07-05
MX2022005014A (es) 2022-05-16
AU2020372647A1 (en) 2022-06-16
JP2023501217A (ja) 2023-01-18
WO2021084068A1 (en) 2021-05-06
CA3156298A1 (en) 2021-05-06
CN114599363A (zh) 2022-06-07
EP4051250A1 (en) 2022-09-07
IL292529A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CO2021006482A2 (es) Ureas cíclicas
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CL2020002891A1 (es) Nuevos derivados de quinolina
BR112019003945A2 (pt) composições oftálmicas
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
MX2022002183A (es) Composiciones de éster de ácido cannabinoide y sus usos.
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
EA202192118A1 (ru) Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен
UA122811C2 (uk) Фармацевтична композиція
BR112022010976A2 (pt) Produtos oral com liberação controlada
JOP20220045A1 (ar) تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها
EA202190096A1 (ru) Композиция, содержащая аналог соматостатина, для радиофармацевтического применения